Ivor Royston

American oncologist and entrepreneur

Ivor Royston is an American oncologist, researcher, and entrepreneur known for his pioneering work in the field of biotechnology and cancer treatment. He is a co-founder of several biotechnology companies and has made significant contributions to the development of monoclonal antibody therapies.

Early Life and Education

Ivor Royston was born in 1945 in New York City. He pursued his undergraduate studies at Johns Hopkins University, where he earned a Bachelor of Arts degree in 1967. Royston then attended Johns Hopkins School of Medicine, receiving his Doctor of Medicine (MD) degree in 1970.

Career

Academic and Research Career

After completing his medical degree, Royston trained in internal medicine at Stanford University and later specialized in oncology. During his time at Stanford, he worked in the laboratory of Dr. Henry Kaplan, where he developed an interest in the use of monoclonal antibodies for cancer treatment.

In 1978, Royston joined the faculty at the University of California, San Diego (UCSD) as an assistant professor of medicine. At UCSD, he continued his research on monoclonal antibodies and their potential applications in oncology.

Entrepreneurial Ventures

In 1979, Royston co-founded Hybritech, one of the first biotechnology companies focused on developing monoclonal antibody technology. Hybritech's success paved the way for the growth of the biotechnology industry in San Diego, which is now a major hub for biotech research and development.

Royston also co-founded Idec Pharmaceuticals in 1985, which later merged with Biogen to form Biogen Idec, now known as Biogen. Idec Pharmaceuticals was instrumental in developing rituximab, a monoclonal antibody used to treat certain types of non-Hodgkin lymphoma.

Current Work

As of 2023, Ivor Royston continues to be active in the biotechnology industry. He serves on the boards of several biotech companies and is involved in venture capital, helping to fund and guide new startups in the field of life sciences.

Contributions to Medicine

Royston's work has had a profound impact on the treatment of cancer. His research and entrepreneurial efforts have led to the development of therapies that have improved the lives of countless patients. Monoclonal antibodies, in particular, have become a cornerstone of modern cancer treatment, thanks in part to Royston's pioneering work.

Awards and Honors

Throughout his career, Ivor Royston has received numerous awards and honors for his contributions to medicine and biotechnology. These include recognition from professional societies and industry groups for his innovative work and leadership in the field.

Personal Life

Ivor Royston is married and has two children. He is known for his philanthropic efforts and support of educational initiatives in the sciences.

Related Pages

• Monoclonal antibody therapy
• Biotechnology
• Cancer treatment
• Biogen
• University of California, San Diego